Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says
Executive Summary
Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12
You may also be interested in...
Gardasil’s Strong Launch May Be Suppressing Merck’s M&A Appetite
The robust growth for Merck's human papillomavirus vaccine Gardasil seen in the first quarter in part reflects initial purchases by state Vaccines for Children programs
Gardasil’s Strong Launch May Be Suppressing Merck’s M&A Appetite
The robust growth for Merck's human papillomavirus vaccine Gardasil seen in the first quarter in part reflects initial purchases by state Vaccines for Children programs
Merck Halts Gardasil Lobbying Efforts Following Discussions With ACIP, AAP
Merck decided to halt lobbying efforts for state legislation requiring vaccination with its human papilloma virus vaccine Gardasil for school entry following discussions with third party stakeholders, including CDC's Advisory Committee on Immunization Practices and the American Academy of Pediatrics, the company said